Top-News
Zurück
Intra-Cellular Therapies
Beiträge:
64
Zugriffe: 25.623 / Heute: 3
Zugriffe: 25.623 / Heute: 3
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi IBEX 35 Doble Apalancado Diario (2x) UCITS ETF Acc
Perf. 12M: +92,82%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +53,00%
Amundi IBEX 35 UCITS ETF Dist
Perf. 12M: +43,33%
Amundi IBEX 35 UCITS ETF Acc
Perf. 12M: +42,84%
old.nasdaq.com/de/symbol/itci/real-time
old.nasdaq.com/de/symbol/itci/real-time
....gibt es Quartalszahlen, die positiv ausfallen sollten.
Natürlich hoffe ich wie du, dass die Zahlen nicht enttäuschen (bestenfalls sogar über Erwartung ausfallen), aber mal von einer komplett negativen Überraschung abgesehen, interessieren mich die Zahlen absolut nicht.
Die Phase 3 Daten zu Lumateperone für bipolar depression Mitte des kommenden Monats sind für mich persönlich das einzig ausschlaggebende Event für mein derzeitiges Investment.
Aber natürlich hast du Recht wenn du sagst: Positive Q-Zahlen plus positive Phase 3 Daten und -schwupp- steht der Kurs weeeeeeit über dem heutigen Niveau.
Deal? ;-)
Die Phase 3 Daten zu Lumateperone für bipolar depression Mitte des kommenden Monats sind für mich persönlich das einzig ausschlaggebende Event für mein derzeitiges Investment.
Aber natürlich hast du Recht wenn du sagst: Positive Q-Zahlen plus positive Phase 3 Daten und -schwupp- steht der Kurs weeeeeeit über dem heutigen Niveau.
Deal? ;-)
...kann Deine Einschätzung nachvollziehen! Als Newcomer hier begrüße ich Deine detaillierte Info! Können wir gemeinsam Ende des Jahres feiern?
Ich stimme dir voll und ganz zu!
Aber positive zahlen heute wären nice, denn 100 % auf den Startkurs von 33 Euro ist besser als 100% auf den Starkurs von 20 Euro ;-)
Also toi toi toi
Aber positive zahlen heute wären nice, denn 100 % auf den Startkurs von 33 Euro ist besser als 100% auf den Starkurs von 20 Euro ;-)
Also toi toi toi
The Company recorded net product sales of CAPLYTA for the first quarter of 2020 of approximately $882,500. No net product sales were reported for the comparable period of 2019.
The Company reported a net loss of $47.4 million, or $0.73 per share (basic and diluted), for the first quarter of 2020 compared to a net loss of $34.8 million, or $0.63 per share (basic and diluted), for the first quarter of 2019.
Research and development (R&D) expenses for the first quarter of 2020 were $16.0 million, compared to $25.0 million for the first quarter of 2019. The $9.0 million decrease is primarily due to lower clinical and non-clinical related costs for lumateperone, manufacturing costs, and is partially offset by higher non-lumateperone related project costs and higher labor costs in the first quarter of 2020.
Selling, general and administrative (SG&A) expenses were $34.1 million for the first quarter of 2020, compared to $11.7 million for the same period in 2019. The increase of $22.4 million is due to an increase of $15.6 million for selling related costs and an increase of $6.8 million for general and administrative costs. The increase in selling related costs is due primarily to hiring a sales force, resulting in an increase in labor expenses of approximately $9.9 million and commercialization costs of $5.8 million. The increase in general and administrative costs is due primarily to an increase in professional fees of approximately $2.1 million, labor related expenses of $1.5 million, and information technology expenses of $1.5 million.
Cash, cash equivalents, restricted cash and investment securities totaled $450.4 million at March 31, 2020, compared to $224.0 million at December 31, 2019. In January 2020, the Company completed a $295.0 million public offering resulting in net proceeds to the Company of approximately $277.0 million from the sale of 10 million shares of its common stock, after deducting underwriting discounts and commissions and offering expenses paid by the Company.
ir.intracellulartherapies.com/...first-quarter-2020-financial
...und die Reaktion darauf.
old.nasdaq.com/de/symbol/itci/real-time
The Company reported a net loss of $47.4 million, or $0.73 per share (basic and diluted), for the first quarter of 2020 compared to a net loss of $34.8 million, or $0.63 per share (basic and diluted), for the first quarter of 2019.
Research and development (R&D) expenses for the first quarter of 2020 were $16.0 million, compared to $25.0 million for the first quarter of 2019. The $9.0 million decrease is primarily due to lower clinical and non-clinical related costs for lumateperone, manufacturing costs, and is partially offset by higher non-lumateperone related project costs and higher labor costs in the first quarter of 2020.
Selling, general and administrative (SG&A) expenses were $34.1 million for the first quarter of 2020, compared to $11.7 million for the same period in 2019. The increase of $22.4 million is due to an increase of $15.6 million for selling related costs and an increase of $6.8 million for general and administrative costs. The increase in selling related costs is due primarily to hiring a sales force, resulting in an increase in labor expenses of approximately $9.9 million and commercialization costs of $5.8 million. The increase in general and administrative costs is due primarily to an increase in professional fees of approximately $2.1 million, labor related expenses of $1.5 million, and information technology expenses of $1.5 million.
Cash, cash equivalents, restricted cash and investment securities totaled $450.4 million at March 31, 2020, compared to $224.0 million at December 31, 2019. In January 2020, the Company completed a $295.0 million public offering resulting in net proceeds to the Company of approximately $277.0 million from the sale of 10 million shares of its common stock, after deducting underwriting discounts and commissions and offering expenses paid by the Company.
ir.intracellulartherapies.com/...first-quarter-2020-financial
...und die Reaktion darauf.
old.nasdaq.com/de/symbol/itci/real-time
..... optimistisch, dass wir bis Ende des Jahres wieder die $35 erreichen.
will ich gar nicht mehr von unten sehen :)
old.nasdaq.com/de/symbol/itci/real-time
old.nasdaq.com/de/symbol/itci/real-time
- auch jetzt läuft da Pferdchen
old.nasdaq.com/de/symbol/itci/real-time
old.nasdaq.com/de/symbol/itci/real-time
aktuell ganz gut
old.nasdaq.com/de/symbol/itci/real-time
old.nasdaq.com/de/symbol/itci/real-time
old.nasdaq.com/de/symbol/itci/premarket
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Intra-Cellular Therapies Inc Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 63 | Intra-Cellular Therapies | Balu4u | Vassago | 13.01.25 12:50 |